Viridian Therapeutics Gestion

Gestion contrôle des critères 1/4

Le PDG Viridian Therapeutics est Steve Mahoney, nommé en Oct2023, a un mandat de 1.08 ans. La rémunération annuelle totale est $ 13.02M, composée du salaire de 0.9% et des bonus 99.1%, y compris les actions et options de la société. détient directement 0.027% des actions de la société, d'une valeur de € 415.18K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.1 ans et 4.1 ans.

Informations clés

Steve Mahoney

Directeur général

US$13.0m

Rémunération totale

Pourcentage du salaire du PDG	0.9%
Durée du mandat du directeur général	1.1yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	1.1yrs
Durée moyenne du mandat des membres du conseil d'administration	4.1yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Steve Mahoney a-t-elle évolué par rapport aux bénéfices de Viridian Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$257m
Jun 30 2024	n/a	n/a	-US$228m
Mar 31 2024	n/a	n/a	-US$218m
Dec 31 2023	US$13m	US$113k	-US$238m

Rémunération vs marché: La rémunération totale de Steve ($USD 13.02M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.64M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Steve avec les performances de l'entreprise.

PDG

Steve Mahoney (53 yo)

1.1yrs

Titularisation

US$13,022,654

Compensation

Mr. Stephen F. Mahoney, also known as Steve, J. D. serves as President, CEO & Director at Viridian Therapeutics, Inc. since October 30, 2023. He served as President, Chief Financial and Operating Officer a...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.027% € 415.2k
Seth Harmon	Senior VP of Finance and Accounting	1.2yrs	US$6.67m	0.0013% € 19.4k
Thomas Beetham	Chief Operating Officer	1.1yrs	US$5.17m	0.0076% € 116.3k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	pas de données	pas de données
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	pas de données	pas de données
Vahe Bedian	Co-Founder & Scientific Advisor	no data	pas de données	pas de données
Jennifer Tousignant	Chief Legal Officer	less than a year	pas de données	pas de données
John Jordan	Vice President of Investor Relations & Corporate Communications	no data	pas de données	pas de données
Melissa Manno	Chief Human Resources Officer	less than a year	pas de données	pas de données
Anthony Casciano	Chief Commercial Officer	1.6yrs	pas de données	pas de données
Thomas Ciulla	Chief Medical Officer	1.8yrs	pas de données	0.00096% € 14.8k

1.1yrs

Durée moyenne de l'emploi

53.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1S1 n'est pas considérée comme expérimentée (ancienneté moyenne 1.1 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Stephen Mahoney	CEO, President & Director	1.1yrs	US$13.02m	0.027% € 415.2k
Eric Olson	Co-Founder & Chairman of Scientific Advisory Board	no data	pas de données	pas de données
Michael Bristow	Co-Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
Marvin Caruthers	Co-Founder & Scientific Advisory Board Member	no data	pas de données	pas de données
Arlene Morris	Independent Director	6.8yrs	US$477.83k	0% € 0
Victor Ambros	Scientific Advisory Board Member	no data	pas de données	pas de données
Stefanie Dimmeler	Scientific Advisory Board Member	no data	pas de données	pas de données
Jeffery Molkentin	Scientific Advisory Board Member	no data	pas de données	pas de données
Eva van Rooij	Scientific Advisory Board Member	no data	pas de données	pas de données
Tomas Kiselak	Independent Chairperson of Board	4.1yrs	US$503.83k	0% € 0
Jennifer Moses	Independent Director	3.3yrs	US$467.83k	0% € 0
Peter Harwin	Independent Director	4.1yrs	US$471.83k	0% € 0

4.1yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1S1 sont considérés comme expérimentés (ancienneté moyenne 4.1 ans).

Viridian Therapeutics Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

CEO, President & Director recently bought €447k worth of stock

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Recent updates

Third quarter 2024 earnings released: US$1.16 loss per share (vs US$1.09 loss in 3Q 2023)

CEO, President & Director recently bought €447k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

First half 2024 earnings released: US$1.82 loss per share (vs US$2.88 loss in 1H 2023)

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought €92k worth of stock

President recently bought €149k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

First quarter 2022 earnings released: US$0.98 loss per share (vs US$2.91 loss in 1Q 2021)

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$2.22 loss per share (vs US$1.82 loss in 2Q 2020)

Independent Director Joseph Turner has left the company

Independent Chairman of the Board Jeffrey Hatfield has left the company

CFO, Secretary & Treasurer has left the company

First quarter 2021 earnings released: US$2.91 loss per share (vs US$2.65 loss in 1Q 2020)

Full year 2020 earnings released: US$31.13 loss per share (vs US$20.04 loss in FY 2019)

New 90-day low: €12.68

Viridian Therapeutics, Inc. Appoints Jonathan Violin, as Chief Executive Officer

miRagen Therapeutics, Inc. Announces Executive Changes

New 90-day high: €18.14

Miragen Therapeutics, Inc. Enters into License Agreement with Xencor for Use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Miragen Therapeutics, Inc. Announces Diana Escolar, M.D. to Resign as the Chief Medical Officer of the Company, Effective as of January 1, 2021

Revenue misses expectations

New 90-day high: €1.04

Miragen Therapeutics, Inc. (NasdaqCM:MGEN) acquired Viridian Therapeutics, Inc. for approximately $110 million.

Miragen Therapeutics, Inc. Announces Management Changes

Analyse de la rémunération des PDG

PDG

Titularisation